• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2021, Vol. 38 ›› Issue (1): 74-78.

• 药物经济学评价 • 上一篇    下一篇

ARB类药物治疗原发性高血压的药物经济学研究

 张丽丽1, 宋沧桑2*, 张阳2, 李兴德2, 毛盼盼2, 张函舒2   

  1. 1. 大理大学,云南 大理 6710002;
    2. 昆明市第一人民医院药学部, 云南 昆明 650000
  • 收稿日期:2020-07-16 修回日期:2021-01-12 出版日期:2021-02-28 发布日期:2021-02-28

Pharmacoeconomic Study of ARB Drugs in the Treatment of Essential Hypertension

  1. 1. Dali University, Yunnan Dali 671000, China;
    2. Department of Pharmacy, The First Hospital of Kunming, Yunnan Kunming 650000, China
  • Received:2020-07-16 Revised:2021-01-12 Online:2021-02-28 Published:2021-02-28

摘要: 目的:对血管紧张素II受体阻滞剂(ARB)类药物治疗原发性高血压的经济学评价文献进行归纳分析,并提出合理的用药指导方案。方法:检索中国知网、万方及PubMed等中英文数据库,对2006—2015年ARB类药物治疗原发性高血压的经济学评价文献进行分析及总结。结果:9组给药方案中有7组包含厄贝沙坦,总有效率分别为72.7%、93%、83%、72.7%、83.3%、83.3%及80.6%,C/E分别为2.33、2.2、7.91、2.21、7.91、7.91及7.93。有2组进行最小成本分析及ΔC/ΔE比值计算后的结果显示,厄贝沙坦成本最低且ΔC/ΔE比值最小。有3组在经过单因素敏感性分析后的结果显示,厄贝沙坦的成本-效果更好。结论:在原发性高血压患者的治疗中,厄贝沙坦是ARB类药物中成本-效果较好、不良反应较少的药物。国内的成本分析范围过于单一,敏感度分析的变量过少,研究结果需要进一步分析。

关键词: font-size:medium, ">药物经济学;血管紧张素II受体阻滞剂(ARB)类药物;成本-效果分析

Abstract: Objective: To summarize and analyze the literature on the economic evaluation of angiotensin II receptor blockers (ARB) in the treatment of essential hypertension, and put forward the reasonable medication guidance scheme. Methods:Chinese and English databases such as CNKI, Wanfang and PubMed were searched to analyze and summarize the literature on the economic evaluation of ARB drugs in the treatment of essential hypertension from 2006 to 2015. Results:The total effective rates were 72.7%、93%、83%、72.7%、83.3%、83.3% and 80.6% respectively, and the C / E were 2.33、2.2、7.91、2.21、7.91、7.91 and 7.93 respectively. The results of minimum cost analysis and ΔC/ΔE ratio calculation in two groups showed that irbesartan had the lowest cost and ΔC/ΔEratio. The results of univariate sensitivity analysis showed that irbesartan was more cost-effective in three groups. Conclusion:Irbesartan is an ARB drug with better cost-effectiveness and less adverse reactions in the treatment of patients with essential hypertension. However, the scope of domestic cost analysis is too single, and the variables of sensitivity analysis are too few, so the research results need further analysis.

Key words: font-size:medium, ">Pharmacoeconomics; Angiotension II receptor blockers (ARBs) drugs; Cost-effectiveness analysis

中图分类号: